The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Open accessAbstract
BACKGROUND: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety. METHODS: Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). The primary end point was overall survival. RESULTS: A total of 573 patients from 85 centers underwent randomization. The median age was 56 years, and 84 percent of patients had undergone debulking surgery. At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 percent confidence interval, 0.52 to 0.75; P<0.001 by the log-rank test). The two-year survival rate was 26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapy alone. Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3 or 4 hematologic toxic effects in 7 percent of patients. CONCLUSIONS: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The standard treatment for high-grade gliomas such as glioblastoma (grade IV) is surgery followed by chemotherapy and radiation therapy [45].”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“Since the current clinically actionable sub-compartments are TC (i.e., considered for surgery) and WT (i.e., considered for radiotherapy)42, performance improvements of their boundary detection may contribute to the model’s clinical impact and relevance.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [42]
In the citing paper
“Stupp et al. originally reported that treatment of patients with GBM with TMZ and radiation resulted in an approximately 20% increase in progression-free survival compared with radiation therapy alone.39”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [39]
In the citing paper
“An effect size of 20% increase in survival was considered to be biologically significant when comparing survival in TMZ versus combination T/N-treated mice.39”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [39]
In the citing paper
“An increase of median survival of 13.4 months for patients treated with a combination of MFH and radiotherapy after glioblastoma recurrence was obtained (Figure 7E). As compared to the abovementioned historical control group, where the median survival after recurrence was 6.2 months, this increase is substantial.”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [223]
In the citing paper
“An increase of median survival of 13.4 months for patients treated with a combination of MFH and radiotherapy after glioblastoma recurrence was obtained (Figure 7E). As compared to the abovementioned historical control group, where the median survival after recurrence was 6.2 months, this increase is substantial.”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [224]
In the citing paper
“It is highly unlikely that this additional technical support would translate into a 3-month prolongation of median survival, which is in the range of the benefit seen with the introduction of TMZ.26”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [26]
In the citing paper
“However, a strong selection bias and inclusion of patients with pseudoprogression after initial TMZ chemoradiotherapy cannot be ruled out in this uncontrolled routine practice patient population.26”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [26]
In the citing paper
“In the PriDE dataset reflecting routine clinical use of the device, patients who received TTFields at first recurrence were treated for a median of 6.2 months and had a median survival of 20 months, comparing favorably with recent trial results investigating other novel agents.”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [26]
In the citing paper
“while the published Temozolomide data indicates an increase of about 20% in OS compared to ionizing radiation treatment alone [14]”
From Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields) (2009) · cites this paper as [14]
In the citing paper
“However, if we assume that the TTFields therapeutic efficacy for newly diagnosed patients is similar to recurrent GBM, i.e. the median of OS is increased by 270% [1] while the published Temozolomide data indicates an increase of about 20% in OS compared to ionizing radiation treatment alone [14], the results presented in Figure 6 point towards additivity between TTFields and Temozolomide.”
From Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields) (2009) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Self-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256
DeAngelis, L. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440207 · Cited by 1,689
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
WALKER, M. D., Alexander, E., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., Norrell, H., Owens, G., Ransohoff, J., Wilson, C. B., et al. (1978) · Journal of neurosurgery · doi:10.3171/jns.1978.49.3.0333 · Cited by 1,684
WALKER, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,618
Pathology and genetics of tumours of the nervous system.
Kleihues, P., & Cavennee, W. (2000) · International Agency for Research on Cancer eBooks · Cited by 1,432
Westphal, M., Hilt, D. C., Bortey, E. B., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J. E., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,374
Curran, W. J., Scott, C., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C., Rotman, M., Asbell, S., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,309
Research works printed but not linked: 5
- Green SB, 1983, Cancer Treat Rep, 67, 121
- Brock CS, 1998, Cancer Res, 58, 4363
- 10.1200/JCO.20.5.1375 · DOI
- Shapiro WR, 1992, Rev Neurol, 148, 428
- Wick W, 2002, Cancer Res, 62, 1915
Cited by
Sorted by citations
Items 401–500 of 1,070
Hombach‐Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C. H., Pitz, M. W., Hamaï, A., Siemianowicz, K., Likus, W., Wiecheć, E., Toyota, B. D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 298
Wen, P. Y., Reardon, D. A., Armstrong, T. S., Phuphanich, S., Aiken, R. D., Landolfi, J. C., Curry, W. T., Zhu, J., Glantz, M., Peereboom, D. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0261 · Cited by 290
Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Stefano, A. L. D., Fucci, A., Frattini, V., Labussière, M., Mokhtari, K., Zoppoli, P., Marie, Y., Bruno, A., Boisselier, B., Giry, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2199 · Cited by 297
Reirradiation Tolerance of the Human Brain
Mayer, R., & Sminia, P. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.08.015 · Cited by 288
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W. P., Bélanger, K., Brandes, A. A., Bogdahn, U., Macdonald, D. R., Forsyth, P. A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f02e1 · Cited by 288
Self-citationChallenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Wang, X., Guo, G., Guan, H., Yu, Y., Lu, J., & Yu, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1085-3 · Cited by 292
NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma
Weiß, T., Weller, M., Gückenberger, M., Sentman, C. L., & Roth, P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1788 · Cited by 291
Self-citationMcCormack, A. I., Dekkers, O. M., Petersenn, S., POPOVIC, V. M., Trouillas, J., Raverot, G., Burman, P., _, _., _, _., Hubalewska-Dydejezky, A., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0933 · Cited by 286
Hamstra, D. A., Chenevert, T. L., Moffat, B. A., Johnson, T. D., Meyer, C. R., Mukherji, S. K., Quint, D. J., Gebarski, S. S., Fan, X., Tsien, C. I., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508347102 · Cited by 285
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., Herndon, J. E., Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D. A., Friedman, A. H., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0124 · Cited by 285
Glioma: experimental models and reality
Lenting, K., Verhaak, R. G. W., ter Laan, M., Wesseling, P., & Leenders, W. P. J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1671-4 · Cited by 300
Advances in Brain Tumor Surgery for Glioblastoma in Adults
Lara-Velazquez, M. A., Al‐kharboosh, R., Jeanneret, S., Vazquez-Ramos, C. A., Mahato, D., Tavanaiepour, D., Rahmathulla, G., & Quiñones‐Hinojosa, A. (2017) · Brain Sciences · doi:10.3390/brainsci7120166 · Cited by 284
Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock
Dong, Z., Zhang, G., Qu, M., Gimple, R. C., Wu, Q., Qiu, Z., Prager, B. C., Wang, X., Kim, L. J. Y., Morton, A. R., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0215 · Cited by 293
Molecular diagnostics of gliomas: state of the art
Riemenschneider, M. J., Jeuken, J. W. M., Wesseling, P., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0736-4 · Cited by 295
Cohen, M. H., Johnson, J. R., & Pazdur, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0722 · Cited by 282
Hutterer, M., Knyazev, P. G., Abate, A., Reschke, M., Maier, H., Stefanova, N., Knyazeva, T., Barbieri, V., Reindl, M., Muigg, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0862 · Cited by 281
Epidemiology of venous thromboembolism in 9489 patients with malignant glioma
Semrad, T. J., OʼDonnell, R. T., Wun, T., Chew, H. K., Harvey, D. J., Zhou, H., & White, R. H. R. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.4.601 · Cited by 280
Chen, L., Li, X., LIU, L., Yu, B., Xue, Y., & Liu, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.3712 · Cited by 286
RetractedBrandes, A. A., Tosoni, A., Spagnolli, F., Frezza, G., Leonardi, M., Calbucci, F., & Franceschi, E. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-008 · Cited by 280
Self-citationPathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue
D’Alessio, A., Proietti, G., Sica, G., & Scicchitano, B. M. (2019) · Cancers · doi:10.3390/cancers11040469 · Cited by 289
Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas
Zhao, Z., Meng, F., Wang, W., Zheng, W., Zhang, C., & Jiang, T. (2017) · Scientific Data · doi:10.1038/sdata.2017.24 · Cited by 281
Recent Advances in Therapy for Glioblastoma
Clarke, J. L., Butowski, N. A., & Chang, S. M. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.5 · Cited by 284
Review Glioblastoma multiforme – an overview
Urbańska, K., Sokołowska, J., Szmidt, M., & Sysa, P. (2014) · Współczesna Onkologia · doi:10.5114/wo.2014.40559 · Cited by 300
Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α
Wang, Q., He, Z., Huang, M., Liu, T., Wang, Y., Xu, H., Duan, H., Ma, P., Zhang, L., Zamvil, S. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03050-0 · Cited by 293
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
Modeling Adult Gliomas Using RCAS/t-va Technology
Hambardzumyan, D., Amankulor, N. M., Helmy, K. Y., Becher, O. J., & Holland, E. C. (2009) · Translational Oncology · doi:10.1593/tlo.09100 · Cited by 277
Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Liang, J., Piao, Y., Holmes, L., Fuller, G. N., Henry, V. K., Tiao, N., & de Groot, J. F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1279 · Cited by 277
Glioblastoma stem‐like cells secrete the pro‐angiogenic VEGF‐A factor in extracellular vesicles
Treps, L., Perret, R. E., Edmond, S., Ricard, D., & Gavard, J. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1359479 · Cited by 285
Liu, H.-L., Fan, C., Ting, C.-Y., & Yeh, C. (2014) · Theranostics · doi:10.7150/thno.8074 · Cited by 275
Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., Geoffroy, F. J., Arusell, R. M., Kitange, G. J., Jenkins, R. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0612 · Cited by 275
Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
Tanaka, K., Babić, I., Nathanson, D. A., Akhavan, D., Guo, D., Gini, B., Dang, J. H. T., Zhu, S., Yang, H., Jesus, J. D., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0124 · Cited by 279
Sarin, H., Kanevsky, A. S., Wu, H., Brimacombe, K. R., Fung, S. H., Sousa, A. A., Auh, S., Wilson, C. M., Sharma, K., Aronova, M. A., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-80 · Cited by 279
Mamelak, A. N., & Jacoby, D. B. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.2.175 · Cited by 274
Anjum, K., Shagufta, B. I., Abbas, S. Q., Patel, S. V., Khan, I., Shah, S. A. A., Akhter, N., & Hassan, S. S. U. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.125 · Cited by 274
RetractedGaillard, P. J., Appeldoorn, C. C. M., Dorland, R., van Kregten, J., Manca, F., Vugts, D. J., Windhorst, A. D., van Dongen, G. A. M. S., de Vries, H. E., Maussang, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082331 · Cited by 273
Sørensen, M. D., Dahlrot, R. H., Boldt, H. B., Hansen, S., & Kristensen, B. W. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12428 · Cited by 279
Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
Verbaanderd, C., Maes, H., Schaaf, M. B. E., Sukhatme, V. P., Pantziarka, P., Sukhatme, V. V., Agostinis, P., & Bouche, G. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.781 · Cited by 282
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C. E., Rutka, J. T., & Zadeh, G. M. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0203-0 · Cited by 293
Cheng, Y., Dai, Q., Morshed, R. A., Fan, X., Wegscheid, M. L., Wainwright, D. A., Han, Y., Zhang, L., Auffinger, B., Tobias, A. L., et al. (2014) · Small · doi:10.1002/smll.201400654 · Cited by 272
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou, J., Patel, T., Sirianni, R. W., Strohbehn, G. W., Zheng, M., Duong, N. T., Schafbauer, T., Huttner, A. J., Huang, Y. H., Carson, R. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304504110 · Cited by 277
Molecular imaging of gliomas with PET: Opportunities and limitations
la Fougère, C. J., Suchorska, B., Bartenstein, P., Kreth, F. W., & Tonn, J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor054 · Cited by 272
WNT signaling in glioblastoma and therapeutic opportunities
Lee, Y., Lee, J., Ahn, S. H., Lee, J., & Nam, D. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.140 · Cited by 278
Zuniga, R. M., Torcuator, R., Jain, R., Anderson, J. E., Doyle, T. J., Ellika, S., Schultz, L., & Mikkelsen, T. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9718-y · Cited by 273
Shaim, H., Shanley, M., Başar, R., Daher, M., Gumin, J., Zamler, D. B., Uprety, N., Wang, F., Huang, Y., Gabrusiewicz, K. R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142116 · Cited by 271
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
Chen, X., Zhang, M., Gan, H., Wang, H., Lee, J., Fang, D., Kitange, G. J., He, L., Hu, Z., Parney, I. F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05373-4 · Cited by 270
Tumor-derived exosomes in the regulation of macrophage polarization
Baig, M. S., Roy, A., Rajpoot, S., Liu, D., Savai, R., Banerjee, S., Kawada, M., Faisal, S. M., Saluja, R., Saqib, U., et al. (2020) · Inflammation Research · doi:10.1007/s00011-020-01318-0 · Cited by 278
Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
Ciardiello, D., Élez, E., Tabernero, J. M., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 279
An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity
Oppenlander, M. E., Wolf, A. B., Snyder, L. A., Bina, R. W., Wilson, J. R., Coons, S. W., Ashby, L. S., Brachman, D. G., Nakaji, P., Porter, R. W., et al. (2014) · Journal of neurosurgery · doi:10.3171/2013.12.jns13184 · Cited by 269
Vleeschouwer, S. D., Fieuws, S., Rutkowski, S., Calenbergh, F. V., Loon, J. V., Goffin, J., Sciot, R., Wilms, G., Demaerel, P., Warmuth‐Metz, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4875 · Cited by 272
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A. C., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 283
Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas
Kwon, C., Zhao, D., Chen, J., Llaguno, S. R. A., Li, Y., Burns, D. K., Mason, R. P., Lee, E. Y.-H. P., Wu, H., & Parada, L. F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6867 · Cited by 268
Lottaz, C., Beier, D., Meyer, K., Kumar, P., Hermann, A., Schwarz, J., Junker, M., Oefner, P. J., Bogdahn, U., Wischhusen, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1707 · Cited by 268
Self-citationAnticancer Mechanisms of Cannabinoids
Velasco, G., Sánchez, C., & Guzmán, M. (2016) · Current Oncology · doi:10.3747/co.23.3080 · Cited by 281
Ringel, F. A., Pape, H., Sabel, M., Krex, D., Bock, H. C., Misch, M., Weyerbrock, A., Westermaier, T., Senft, C., Schucht, P., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov145 · Cited by 266
Nance, E. A., Zhang, C., Shih, T.-Y., Xu, Q., Schuster, B. S., & Hanes, J. S. (2014) · ACS Nano · doi:10.1021/nn504210g · Cited by 272
Galldiks, N., Dunkl, V., Stoffels, G., Hutterer, M., Rapp, M., Sabel, M., Reifenberger, G., Kebir, S., Dorn, F., Blau, T., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2959-4 · Cited by 266
Zuccoli, G., Marcello, N., Pisanello, A., Servadei, F., Vaccaro, S., Mukherjee, P., & Seyfried, T. N. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-33 · Cited by 266
Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic DevelopmentPreprint
Zong, H., Parada, L. F., & Baker, S. J. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020610 · Cited by 281
Sun, Y., Ding, M., Zeng, X., Xiao, Y., Wu, H., Zhou, H., Ding, B., Qu, C., Hou, W., Aga, E.-B., et al. (2017) · Chemical Science · doi:10.1039/c7sc00251c · Cited by 265
Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients
Osti, D., Bene, M. D., Rappa, G., Santos, M. F., Matafora, V., Richichi, C., Faletti, S., Beznoussenko, G. V., Mironov, A., Bachi, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1941 · Cited by 278
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
Jiang, N., Xie, B., Xiao, W., Fan, M., Xu, S., Duan, Y., Hamsafar, Y., Evans, A. C., Huang, J., Zhou, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29137-3 · Cited by 267
Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme
Zinn, P. O., Majadan, B., Sathyan, P., Singh, S. K., Majumder, S., Jolesz, F. A., & Colen, R. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025451 · Cited by 269
Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules
Leder, K., Pitter, K. L., LaPlant, Q. C., Hambardzumyan, D., Ross, B. D., Chan, T. A.-T., Holland, E. C., & Michor, F. (2014) · Cell · doi:10.1016/j.cell.2013.12.029 · Cited by 269
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Using the molecular classification of glioblastoma to inform personalized treatment
Olar, A., & Aldape, K. (2013) · The Journal of Pathology · doi:10.1002/path.4282 · Cited by 278
Angiogenesis and invasion in glioma
Onishi, M., Ichikawa, T., Kurozumi, K., & Date, I. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-010-0007-z · Cited by 271
Central Nervous System Cancers
Nabors, B., Ammirati, M., Bierman, P. J., Brem, H., Butowski, N. A., Chamberlain, M. C., DeAngelis, L. M., Fenstermaker, R. A., Friedman, A. H., Gilbert, M. R., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0132 · Cited by 260
Aberrant Signaling Pathways in Glioma
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J. (2011) · Cancers · doi:10.3390/cancers3033242 · Cited by 277
Wick, A., Felsberg, J., Steinbach, J. P., Herrlinger, U., Platten, M., Blaschke, B., Meyermann, R., Reifenberger, G., Weller, M., & Wick, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7722 · Cited by 260
Self-citationvan Dijken, B. R. J., van Laar, P. J., Holtman, G. A., & van der Hoorn, A. (2017) · European Radiology · doi:10.1007/s00330-017-4789-9 · Cited by 260
Buccarelli, M., Marconi, M., Pacioni, S., Pascalis, I. D., D’Alessandris, Q. G., Martini, M., Ascione, B., Malorni, W., Larocca, L. M., Pallini, R., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0864-7 · Cited by 262
Current Standards of Care in Glioblastoma Therapy
Fernandes, C. D., Costa, A., Osório, L., Lago, R. C., Linhares, P., Carvalho, B., & Caeiro, C. (2017) · Codon Publications eBooks · doi:10.15586/codon.glioblastoma.2017.ch11 · Cited by 275
Chukwueke, U. N., & Wen, P. Y. (2019) · CNS Oncology · doi:10.2217/cns-2018-0007 · Cited by 262
Sukumar, U. K., Bose, R. J., Malhotra, M., Babikir, H. A., Afjei, R., Robinson, E. R., Zeng, Y., Chang, E., Habte, F. G., Sinclair, R., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119342 · Cited by 265
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P. V., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 265
Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management
Wang, Y., & Jiang, T. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.12.024 · Cited by 264
Marie-Egyptienne, D. T., Lohse, I., & Hill, R. P. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.019 · Cited by 264
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K., Marzo, A. M. D., Hammond, M. E. H., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 262
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Wrensch, M., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq497 · Cited by 261
Suchorska, B., Weller, M., Tabatabai, G., Senft, C., Hau, P., Sabel, M., Herrlinger, U., Ketter, R., Schlegel, U. S., Marosi, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov326 · Cited by 268
Self-citationZhao, H., Wang, J., Shao, W., Wu, C.-P., Chen, Z.-P., To, S.-S. T., & Li, W.-P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0670-3 · Cited by 255
Circulating biomarkers in patients with glioblastoma
Bark, J. M., Kulasinghe, A., Chua, B., Day, B. W., & Punyadeera, C. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0603-6 · Cited by 262
Portnow, J., Badie, B., Chen, M., Liu, A., Blanchard, S., & Synold, T. W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1349 · Cited by 254
Carbon Ion Therapy: A Modern Review of an Emerging Technology
Malouff, T. D., Mahajan, A., Krishnan, S., Beltran, C. J., Seneviratne, D. S., & Trifiletti, D. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00082 · Cited by 254
Salmaggi, A., Boiardi, A., Gelati, M., Russo, A., Calatozzolo, C., Ciusani, E., Sciacca, F. L., Ottolina, A., Parati, E. A., Porta, C. A. M. L., et al. (2006) · Glia · doi:10.1002/glia.20414 · Cited by 253
van den Bent, M. J., Dubbink, H. J., Sanson, M., van der Lee-Haarloo, C. R., Hegi, M. E., Jeuken, J. W. M., Ibdaih, A., Brandes, A. A., TAPHOORN, M. J. B., Frénay, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1034 · Cited by 253
Self-citationPatel, P., Baradaran, H., Delgado, D., Askin, G., Christos, P. J., Tsiouris, A. J., & Gupta, A. K. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now148 · Cited by 257
Selective Targeting of Brain Tumors with Gold Nanoparticle-Induced Radiosensitization
Joh, D. Y., Sun, L., Stangl, M., Zaki, A. A., Murty, S., Santoiemma, P. P., Davis, J. J., Baumann, B. C., Alonso‐Basanta, M., Bhang, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062425 · Cited by 264
The Pathobiology of Glioma Tumors
Gladson, C. L., Prayson, R. A., & Liu, W. M. (2009) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102109 · Cited by 268
Polymeric Nanoparticles for Nonviral Gene Therapy Extend Brain Tumor Survival in Vivo
Mangraviti, A., Tzeng, S. Y., Kozielski, K., Wang, Y., Jin, Y., Gullotti, D. M., Pedone, M., Buaron, N., Liu, A., Wilson, D. R., et al. (2015) · ACS Nano · doi:10.1021/nn504905q · Cited by 251
Li, G., Wang, D., Zhai, Y., Pan, C., Zhang, J., Wang, C., Huang, R., Yu, M., Li, Y., Liu, X., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.011 · Cited by 257
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0671-1 · Cited by 256
Verdugo, E., Puerto, I., & Medina, M. Á. (2022) · 癌症：英文版 · doi:10.1002/cac2.12361 · Cited by 250
A realistic appraisal of boron neutron capture therapy as a cancer treatment modality
Barth, R. F., Zhang, Z., & Liu, T. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0280-5 · Cited by 249
Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications
Parker, N., Khong, P., Parkinson, J., Howell, V. M., & Wheeler, H. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00055 · Cited by 263
Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric Plasma
Köritzer, J., Boxhammer, V., Schäfer, A., Shimizu, T., Klämpfl, T. G., Li, Y., Welz, C., Schwenk‐Zieger, S., Morfill, G. E., Zimmermann, J. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064498 · Cited by 248
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Brada, M., Stenning, S. P., Gabe, R., Thompson, L. C., Levy, D., Rampling, R., Erridge, S., Saran, F. H., Gattamaneni, R., Hopkins, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1932 · Cited by 248
Goodman, A. M., Piccioni, D. E., Kato, S., Boichard, A., Wang, H., Frampton, G. M., Lippman, S. M., Connelly, C. F., Fabrizio, D. A., Miller, V. A., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1701 · Cited by 250
Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma
Sloan, A. E., Ahluwalia, M. S., Valerio-Pascua, J., Manjila, S. V., Torchia, M. G., Jones, S. E., Sunshine, J. L., Phillips, M., Griswold, M. A., Clampitt, M. E., et al. (2013) · Journal of neurosurgery · doi:10.3171/2013.1.jns1291 · Cited by 247
Potts, B. C. M., Albitar, M. X., Anderson, K. C., Baritaki, S., Berkers, C. R., Bonavida, B., Chandra, J., Chauhan, D., Cusack, J. C., Fenical, W., et al. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519716 · Cited by 247
Metadata
- Authors
- Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., & Mirimanoff, R. O.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Princess Margaret Cancer Centre (CA)
- University of Tübingen (DE)
- Western University (CA)
- University Medical Center Utrecht (NL)
- Azienda Ospedale - Università Padova (IT)
- Medical University of Vienna (AT)
- University Hospital Regensburg (DE)
- University Hospital of Bern (CH)
- Queen's University (CA)
- European Organisation for Research and Treatment of Cancer (NL)
- University of Calgary (CA)
- Canadian Cancer Trials Group (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-10
- Volume
- 352
- Issue
- 10
- Pages
- 987-996
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096287682
- Cited by
- 21,807
- References
- 35
- Citations by year
- 2026: 1259 · 2025: 1369 · 2024: 1444 · 2023: 1500 · 2022: 1532 · 2021: 1614 · 2020: 1453 · 2019: 1256 · 2018: 1167 · 2017: 1156 · 2016: 1068 · 2015: 1110 · 2014: 1019 · 2013: 901 · 2012: 872
- FWCI
- 171.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion, other-oa)
- Funders
- National Cancer Institute (5U10-CA11488-30, 5U10-CA11488-32, 5U10-CA11488-33, 5U10-CA11488-31, U10CA011488, 5U10 CA11488-34)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
- Keywords
- glioblastoma, temozolomide, radiotherapy, concurrent chemoradiotherapy, adjuvant chemotherapy, overall survival, hematologic toxicity, newly diagnosed brain tumors
- MeSH terms
- Temozolomide, Adrenal Cortex Hormones, Adult, Aged, Brain Neoplasms, Dacarbazine, Female, Glioblastoma, Humans, Male, Middle Aged, Radiotherapy, Computer-Assisted, Proportional Hazards Models, Survival Analysis, Chemotherapy, Adjuvant, Disease Progression, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
